Edition:
India

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

29.29USD
1:30am IST
Change (% chg)

$-0.16 (-0.54%)
Prev Close
$29.45
Open
$29.44
Day's High
$29.70
Day's Low
$29.10
Volume
130,785
Avg. Vol
449,859
52-wk High
$52.63
52-wk Low
$24.45

Select another date:

Wed, Mar 28 2018

BRIEF-The Medicines Company Announces Chief Financial Officer Transition

* THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

BRIEF-Medicines Co Says Board Appointed Christopher Visioli As CFO

* MEDICINES - ON MARCH 21, BOARD APPOINTED CHRISTOPHER VISIOLI CFO AND TREASURER OF COMPANY, EFFECTIVE IMMEDIATELY

Medicines Company cuts board size, activist Denner to get more control

March 1 Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

BRIEF-The Medicines Company Appoints Sarah Schlesinger To Its Board Of Directors

* THE MEDICINES COMPANY APPOINTS SARAH SCHLESINGER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2muRQBT) Further company coverage:

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

Select another date: